Pharming Group Beheer

Beheer criteriumcontroles 2/4

De CEO Pharming Group is Simon de Vries, benoemd in Nov2008, heeft een ambtstermijn van 16.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.81M, bestaande uit 24% salaris en 76% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.13% van de aandelen van het bedrijf, ter waarde € 10.48M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 3.7 jaar.

Belangrijke informatie

Simon de Vries

Algemeen directeur

US$2.8m

Totale compensatie

Percentage CEO-salaris	24.0%
Dienstverband CEO	16yrs
Eigendom CEO	2.1%
Management gemiddelde ambtstermijn	3.8yrs
Gemiddelde ambtstermijn bestuur	3.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Simon de Vries's beloning veranderd ten opzichte van Pharming Group's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$18m
Jun 30 2024	n/a	n/a	-US$13m
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$3m	US$673k	-US$11m
Sep 30 2023	n/a	n/a	-US$22m
Jun 30 2023	n/a	n/a	-US$16m
Mar 31 2023	n/a	n/a	-US$2m
Dec 31 2022	US$2m	US$636k	US$14m
Sep 30 2022	n/a	n/a	US$30m
Jun 30 2022	n/a	n/a	US$21m
Mar 31 2022	n/a	n/a	US$11m
Dec 31 2021	US$3m	US$681k	US$16m
Sep 30 2021	n/a	n/a	US$22m
Jun 30 2021	n/a	n/a	US$31m
Mar 31 2021	n/a	n/a	US$37m
Dec 31 2020	US$3m	US$614k	US$38m
Sep 30 2020	n/a	n/a	US$44m
Jun 30 2020	n/a	n/a	US$46m
Mar 31 2020	n/a	n/a	US$42m
Jan 01 2020	n/a	n/a	US$41m
Sep 30 2019	n/a	n/a	US$38m
Jun 30 2019	n/a	n/a	US$34m
Mar 31 2019	n/a	n/a	US$29m
Dec 31 2018	US$2m	US$579k	US$29m
Sep 30 2018	n/a	n/a	-US$29m
Jun 30 2018	n/a	n/a	-US$44m
Mar 31 2018	n/a	n/a	-US$80m
Dec 31 2017	US$2m	US$537k	-US$91m

Compensatie versus markt: De totale vergoeding ($USD 2.81M ) Simon } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 995.46K ).

Compensatie versus inkomsten: De vergoeding van Simon is gestegen terwijl het bedrijf verliesgevend is.

CEO

Simon de Vries (65 yo)

16yrs

Tenure

US$2,809,000

Compensatie

Dr. Sijmen De Vries, also known as Simon, M. D., M. B.A., has been the Chief Executive Officer of Pharming Group N. V. since November 03, 2008 and also serves as its Executive Director since October 13, 20...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Sijmen de Vries	President	16yrs	US$2.81m	2.13% € 10.5m
Jeroen Wakkerman	Chief Financial Officer	4yrs	geen gegevens	0.064% € 312.1k
Mireille Sanders	Chief Operations Officer	5.3yrs	geen gegevens	0.12% € 578.9k
Susanne Embleton	Investor Relations Manager	no data	geen gegevens	geen gegevens
Ruud Van Outersterp	Chief Ethics & Compliance Officer	3.5yrs	geen gegevens	0.024% € 119.7k
Anurag Relan	Chief Medical Officer	3.4yrs	geen gegevens	0.027% € 133.5k
Stephen Toor	Chief Commercial Officer & GM Americas	7.8yrs	geen gegevens	0.028% € 136.0k
Alexander Breidenbach	Chief Business Officer	1.2yrs	geen gegevens	0.0096% € 47.3k
Bruno M. Giannetti	Consultant	3.4yrs	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0QCO wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Sijmen de Vries	President	16.1yrs	US$2.81m	2.13% € 10.5m
Leonard Kruimer	Independent Non-Executive Director	3.5yrs	US$90.00k	0.018% € 87.8k
Mark Pykett	Independent Non-Executive Director	3.9yrs	US$87.00k	0.022% € 105.8k
Deborah Jorn	Independent Non-Executive Vice-Chairperson	5.5yrs	US$87.00k	0.024% € 117.1k
Steven Baert	Independent Non-Executive Director	3.5yrs	US$90.00k	0.018% € 87.8k
Barbara Yanni	Independent Non-Executive Director	3.9yrs	US$94.00k	0.022% € 105.8k
Richard Peters	Non-Executive Chairman of Board	1.2yrs	US$46.00k	0.0093% € 45.6k
Jabine van der Meijs	Independent Non-Executive Director	3.5yrs	US$94.00k	0.018% € 87.8k

3.7yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0QCO wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).

Pharming Group Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Pharming Group N.V. Appoints Richard Peters as Non-Executive Director

Pharming Group N.V. Appoints Alexander Breidenbach as Chief Business Officer

Pharming Group N.V. Approves the Proposal to Reappoint Paul Sekhri, Chair of the Board, as Non-Executive Director for A Period of One Year Who Will Resign from the Board Upon Appointment of His Successor

High number of new directors

High number of new directors

Recent updates

Third quarter 2024 earnings released: US$0.002 loss per share (vs US$0.005 profit in 3Q 2023)

Pharming Group Announces Start of Phase II Clinical Trial of Leniolisib for Primary Immunodeficiencies (PIDs) with Immune Dysregulation

Second quarter 2024 earnings released: US$0.002 loss per share (vs US$0.002 profit in 2Q 2023)

Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union

Insufficient new directors

Pharming Group N.V. Provides Revenue Guidance for 2024

First quarter 2024 earnings released: US$0.019 loss per share (vs US$0.019 loss in 1Q 2023)

Pharming Group N.V. announced that it expects to receive €100 million in funding

Full year 2023 earnings released: US$0.015 loss per share (vs US$0.021 profit in FY 2022)

Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024

Pharming Group N.V. to Report Q4, 2023 Results on Mar 14, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: US$0.005 (vs US$0.014 in 3Q 2022)

Pharming Group N.V. Appoints Richard Peters as Non-Executive Director

Pharming Group N.V. Announces First Patient Enrolled in Phase Iii Clinical Trial of Leniolisib for the Treatment of Apds in Japan

First half 2023 earnings released: US$0.017 loss per share (vs US$0.03 profit in 1H 2022)

Pharming Group N.V. Appoints Alexander Breidenbach as Chief Business Officer

Now 20% undervalued

Pharming Group N.V. Approves the Proposal to Reappoint Paul Sekhri, Chair of the Board, as Non-Executive Director for A Period of One Year Who Will Resign from the Board Upon Appointment of His Successor

Investor sentiment improves as stock rises 15%

Investor sentiment improves as stock rises 26%

Full year 2022 earnings released: EPS: US$0.021 (vs US$0.025 in FY 2021)

Pharming Group N.V. Provides Update on EMA Regulatory Review of Leniolisib for Apds in Europe

Now 20% undervalued

Now 22% undervalued

Investor sentiment improved over the past week

Pharming Group N.V. Announces Positive Interim Analysis Data from Open-Label Extension Study of Leniolisib in Presentation At the 64Th American Society of Hematology (ASH) Annual Meeting and Exposition

Pharming Group N.V. to Report Fiscal Year 2022 Results on Mar 16, 2023

Pharming Group N.V. Announces Positive Results of Phase 3 Clinical Trial of Investigational Drug Leniolisib

High number of new directors

Investor sentiment improved over the past week

Pharming Group N.V. Announces European Medicines Agency Validates its Marketing Authorisation Application Under Accelerated Assessment for Leniolisib

Third quarter 2022 earnings released: EPS: US$0.014 (vs US$0 in 3Q 2021)

Pharming Group N.V. Submits Marketing Authorisation Application to European Medicines Agency for Leniolisib

Pharming Group N.V. Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: US$0.025 (vs US$0.009 in 2Q 2021)

Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency

Pharming Group N.V. Receives Accelerated Assessment in Europe for Leniolisib for the Treatment of Rare Immunodeficiency, APDS

First quarter 2022 earnings released: EPS: US$0.005 (vs US$0.013 in 1Q 2021)

GIMV NV (ENXTBR:GIMB) completed the acquisition of 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM).

High number of new directors

Pharming Receives Agreement of Paediatric Investigation Plan and Promising Innovative Medicine Designation for Leniolisib from UK MHRA

GIMV NV (ENXTBR:GIMB) reached an agreement to acquire 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM) for ?6.9 million.

Pharming Group N.V. Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Pharming Group N.V. Announces Positive Results of Phase II/III Pivotal Clinical Study of Leniolisib for the Treatment of Activated PI3K Delta Syndrome

Pharming Receives Positive European Medicines Agency Decision on Paediatric Investigation Plan for Leniolisib in Europe

Pharming Announces Results from Clinical Trials for the Treatment of COVID-19 with RUCONEST®

Second quarter 2021 earnings released: EPS €0.008 (vs €0.016 in 2Q 2020)

Pharming Group N.V Announces Completion of Enrolment in Phase II/III Study with Leniolisib for Activated Pi3k Delta Syndrome

Independent Non-Executive Director has left the company

Independent Non-Executive Director has left the company

First quarter 2021 earnings released: EPS €0.011 (vs €0.013 in 1Q 2020)

Full year 2020 earnings released: EPS €0.052 (vs €0.058 in FY 2019)

Executive Director & CEO recently bought €489k worth of stock

Pharming Group N.V. to Report Fiscal Year 2020 Final Results on Apr 06, 2021

Full year 2020 earnings released: EPS €0.051 (vs €0.058 in FY 2019)

Revenue beats expectations

Pharming Group N.V. to Report First Half, 2021 Results on Aug 05, 2021

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: €1.21

Pharming Group N.V. Announces Board Appointments

Revenue misses expectations

Third quarter 2020 earnings released: EPS €0.011

Market bids up stock over the past week

New 90-day high: €1.19